Plasma level of von Willebrand factor: An indicator of severity in sickle cell disease

Nawal , Eltayeb Omer; Maria M.  Hamad Satti; Abdelrahim  Osman Mohamed

doi:10.52981/sjms.v4i2.1002

Nawal , Eltayeb Omer University of El Imam El Mahdi
Maria M. Hamad Satti University of Khartoum,
Abdelrahim Osman Mohamed University of El Imam El Mahdi

DOI: https://doi.org/10.52981/sjms.v4i2.1002

الملخص

Background: Sickle cell anaemia is a congenital hemolytic disorder caused by mutation in the â-globin gene at position 6 with replacement of glutamic acid by valine. Patients who arehomozygous for this mutation suffer from hemolytic anaemia and other serious complications. The
underlying pathology of much of these complications is the occurrence of recurrent vasoocclusion due to microthrombi formation resulting in organs ischaemia.

Methods: In this study we investigated the role of vWF as a determinant of sickle cell disease severity through its contribution to the formation of such microthrombi. The clinical disease severity was determined using two different scoring methods, and vWF antigen level in the plasma was estimated by using ELISA technique.

Results and discussion: Seventy Sudanese patients were investigated in this study. They were 35 females and 35 males, the mean of their ages± standard deviation was 6.8 ± 4.7 years. Seventeen controls with normal haemoglobin were also included with mean age of 6.5 years. Thirty four patients presented during vasoocclusive crisis and 36 presented in steady state. vWF was high (179.83%) among patients compared to controls (82.4%), p< 0.001. there was positive correlation between severity score and vWF level in the plasma in steady state in the two scoring methods used ( r = 0.79, p = 0.008 for method I and r = 0.78, p = 0.009 for method II). So, Severity of sickle cell disease increases with elevation of vWF level in the plasma in the steady state

المراجع

1. Mohamed AO. Sickle cell disease in the Sudan:clinical and biochemical aspects. Upsala J Med Sci1993, 201-228
2. Hebbel RP, Boogaerts MA, Eaton JWet al.Erythrocyte adherence to endothelium in sickle cellanaemia. A possible determinant of disease severity.New Engl J Med 1992; 302, 992-995.
3. Ketty L, Pierre G, Francoise RT et al. The nonexpressionof CD36 on reticulocytes and mature redblood cells does not modify the clinical course ofpatients with sickle cell anaemia. Blood 2001; 98(4),966-971.
4. Serjeant GR. Natural history and determinants ofclinical severity of sickle cell disease. Curr OpinHematol 1995; 2 (2), 103-108.
5. Platt OS, Thorington BD, Brambilla DJ et al. Painin sickle cell disease. Rates & Risk Factors. New EnglJ Med 1991; 5(1),11-16.
6. John MH. Introduction: antiadhesive therapy insickle cell disease. Blood 2000; 5(2), 365-376.
7. Richardson SG, Mathews KB, Stuart J et al. Serialchanges in coagulation and viscosity during sickle cellcrisis. Br J Haematol 1979; 41, 95-103.
8. Key NS, Slungaard A, Dandelet L. Whole bloodtissue factor procoagulant activity is elevated inpatients with sickle cell disease. Blood 1998; 91, 4216-4223.
9. Alkjaersig N, Fletcher A, Joist H et al. Haemostaticalterations accompanying sickle cell pain crisis. J LabClin Med 1976; 88, 440-449.
10. Hofstra TC, Karla VK, Meiselman HJ et al. Sickleerythrocytes adhere to polymorphnuclear neutrophilsand activate neutrophil respiratory burst.Blood 1996; 87, 4440-4447.
11. Kaul DK, Hebbel RP. Hypoxia, reoxygenationcauses inflammatory response in transgenic sickle micebut not in normal mice. J Clin Invest 1996; 106, 411-420.
12. Wun T, Paglicroni T, Tablin F et al. Plateletactivation and platelet-erythrocytes aggregates inpatients with sickle cell disease. J Lab Clin Med 1997;129, 507-516.
13. Ruggeri ZM, Ware J. Von Willebrand factors.FASEB 1993; 7, 308-316.
14. Scott T, Miller L, Asleeper CH et al. Prediction ofadverse outcome in children with sickle cell disease.New Engl J Med 2000; 342(2), 83-89.
15. Browne PV, Mosher D, Steinberg MH et al.Disturbances of plasma and platelet thrombospondinlevels in Sickle cell anaemia. Am J Haematol 1996; 51,296-301.
16. Ikeda Y, Handa M, Kawanok et al. The role of vonWillebrand factor and fibrinogen in plateletaggregation under varying shear stress. J Clin Invest1991; 87(4), 1234 -1240.
17. Kaul DK, Nagel RL, Chen D et al. Sickleerythrocyte-endothelial interactions inmicrocirculation: the role of von Willebrand factor andimplications for vaso-occlusion. Blood 1993; 81(9),2429-2438.
18. Leslie J, Langler D, Serjeant GR et al. Coagulationchanges during the steady state in homozygous Sicklecell disease in Jamaica. Br J Haematol 1975; 30, 159-166.
19. Shinya G, Daniel R, Salamon Y et al.Characterization of the unique mechanism mediatingthe shear-dependent binding of soluble von Willebrandfactor to platelets. J Biol Chem 1995; 270(40), 23352-23361.
20. Nichols TC, Bellinger DA, Reddick RL et al. Roleof von wellibrand factor in arterial thrombosis. Studiesin normal and von wellibrand disease pigs. Circulation1991; 83, 56-64.
21. Finch A, Davic E, Sorlie P et al. Association offactor VIII and von Willebrand factor with age, race,sex and risk factors for atherosclerosis. Theaherosclerosis risk in communities (ARIC) study.Thromb Haemost 1993; 70(3), 380-385.
22. Abildgaard CF, Simone JV, Schulman I. FactorVIII (antihaemophilic factor) activity in sickle cellanaemia. Br J haematol 1967; 13, 19-27.
23. Edson JR, Krivit W, White JG. Kaolin partialthromboplastin time: high levels of procoagulantsproducing short clotting times or masking deficienciesof other procoagulants or low concentrations ofanticoagulants. J Lab Clin Med 1967; 70, 463-470.